Latest Breaking News On - Christopher viehbacher - Page 4 : comparemela.com

Biogen Stock Drops as Earnings and Guidance Disappoint

Biogen’s new CEO, Christopher Viehbacher, said the company is well positioned to return to sustainable growth.

Michael-yee
Josh-nathan-kazis
Christopher-viehbacher
Vanessa-leroy-bloomberg
Drug-administration
Wall-street
Sage-therapeutics
Article-normal
Energy
Oil-and-gas-upstream-operations
Biotechnology-services

Biogen fourth-quarter profit misses on Aduhelm exit costs

Biogen missed Wall Street estimates for fourth-quarter profit on Tuesday following its decision last month to return the rights for Alzheimer s disease drug Aduhelm and on soft sales of multiple.

Bengaluru
Karnataka
India
Christopher-viehbacher
Manas-mishra
Shounak-dasgupta
Sriparna-roy
Reuters
Wall-street
Markets

Biogen (BIIB) earnings Q4 2023

The results come amid the rollout of Biogen and Eisai's Leqembi, the first drug found to slow the progression of Alzheimer's to win FDA approval.

Eisai-leqembi
Christopher-viehbacher
Drug-administration
Wall-street
Reata-pharmaceuticals
Sage-therapeutics
Breaking-news
Business
Biotechnology
Biotech-and-pharmaceuticals
Pharmaceuticals
Health-care-industry

Biogen expects to return to profit growth this year

Biogen forecast a return to annual profit growth following cost cuts and a pick up in sales of its newer drugs, but the company s shares fell 5% in premarket trading on Tuesday after missing Wall.

Bengaluru
Karnataka
India
Shounak-dasgupta
Christopher-viehbacher
Manas-mishra
Sriparna-roy
Reuters
Wall-street
Markets

Biogen (BIIB) falls as earnings, revenue misses consensus

Biogen (BIIB) falls as earnings, revenue misses consensus
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Christopher-viehbacher
Sam-boughedda